Business, energy, technology, markets and global industry news from Business News Today

Sobi

PharmaDeviceNews Sobi
Innate Pharma’s lacutamab partnership with Sobi could unlock the TELLOMAK-3 Phase 3 trial and a potential accelerated approval pathway in T-cell lymphoma, with the licensing agreement carrying up to $580 million in potential value. Representative image.
Pharma & Biotech

What Sobi’s lacutamab licensing deal means for Innate Pharma and TELLOMAK-3

Innate Pharma’s Sobi deal brings $75m upfront and could unlock TELLOMAK-3, accelerated approval and global commercialization of lacutamab.

Read More
Representative image of ICU-based sepsis care and immune pathway monitoring, relevant to the EMBRACE clinical trial evaluating emapalumab in interferon-gamma-driven sepsis (IDS).
Pharma & Biotech

Sepsis breakthrough? What the EMBRACE trial reveals about Sobi’s emapalumab strategy

Swedish Orphan Biovitrum AB (Sobi) has reported positive topline data from the Phase 2a EMBRACE trial of Gamifant (emapalumab) in interferon-gamma-driven sepsis (IDS), demonstrating organ function improvement and a potential survival benefit. Based on the signal, the drug will advance in development in collaboration with the Hellenic Institute for the Study of Sepsis (HISS). The

Read More